Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

New England Journal of Medicine

Volumn 339, Issue 7, 1998, Pages 436-443

  Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPTAPEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0008926519     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808133390704     Document Type: Article

References (41)

1. Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engl J Med 1992;327:192-4.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
3. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
4. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35. [Erratum, Lancet 1997;350:744.]
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
6. The RESTORE Study Group. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
7. Alexander IH, Alexander K, Kong DF, Tung CY, Whellan D. Session highlights from the American Heart Association Scientific Sessions: November 9-12, 1997. Am Heart J 1998;135:157-80.
8. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-43.
9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
10. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
11. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56.
12. Klootwijk P, Meij S, Melkert R, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). J Am Coll Cardiol 1997;29:Suppl A:367A. abstract.
13. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
14. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995;91:2151-7.
15. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
16. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
17. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996;94:2083-9.
18. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol 1997;80:Suppl 4A:34B-38B.
19. Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, Hochman JS. An improved regimen for heparin use in acute coronary syndromes. Circulation 1997;96:Suppl I:I-597. abstract.
20. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
21. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies tor acute myocardial infarction. N Engl J Med 1993;329:673-82.
22. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-54.
23. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
24. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plann Inference 1994;42:19-35.
25. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
26. Thrombolysis in Myocardial Ischemia (TIMI) Study Group. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89:1545-56.
27. Serruys PW, Herrman J-PR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
28. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-9.
29. Yusuf S, Wittes J, Probsfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
30. Van de Werf F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. JAMA 1995;273:1586-91.
31. Mahaffey KW, Granger CB, Tardiff BE, et al. Endpoint adjudication by a Clinical Events Committee can impact the statistical outcome of a clinical trial: results from GUSTO-IIb. J Am Coll Cardiol 1997;29:Suppl A:410A. abstract.
32. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 1996;94:3369-75.
33. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-9.
34. Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation 1995;91:2158-66.
35. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-91.
36. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery: EPIC Investigators. Am J Cardiol 1994;74:1166-70.
37. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-30.
38. The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin tor acute coronary syndromes. Circulation 1994;90:1631-7.
39. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
40. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
41. The PARAGON Investigators. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina. Circulation 1998;97:2386-95.